Clinical And Morphological Prognostic Factors For Breast Cancer Patients With Metastatic Ovarian Involvement
Objective of the research - is to study clinical and morphological prognostic factors for breast cancer patients with metastatic ovarian lesion. Materials and Methods. The research comprised breast cancer patients with ovarian metastases and without ovarian metastases that made up the main experimental group and control group comparable to each other in major clinical and demographic factors. It is highlighted that metastatic ovarian lesion in breast cancer is diagnosed simultaneously with the detection of primary tumor which predetermines a different type of the course of disease. Results. On the basis of immunohistochemical indicators metastatic ovarian tumors in breast cancer don't have statistically signifi cant differences from primary tumor, which in turn requires consideration in the choice of treatment strategy for breast cancer progression with ovarian metastases. Analysis of the long-term indicators proved that the presence of ovarian metastases is a signifi cant unfavorable prognostic factor of overall 3-year survival of patients older than 50 years of age in menopause who received integrated treatment. Conclusion. Despite high sensitivity of breast cancer to chemotherapy integrated treatment performed for patients with ovarian metastases doesn't substantially affect overall survival and only surgical treatment reliably increases 3- and 5-year survival rate of patients (83,3%) which may be conditioned by including in the study of patients, who had initially had metastases into other organs (liver, lungs, bones) and received integrated treatment.